0811 GMT - Novartis is set to overcome a wave of patent expirations during 2025, Deutsche Bank analyst Emmanuel Papadakis says in a note. The Swiss pharma giant surprised with its margin performance in the last quarter and its 2025 outlook that came ahead of analysts expectations, he says. While some of the 4Q revenue beat was attributed to rebates, Novartis appears well-positioned to continue exceeding market expectations, the analyst says. Deutsche Bank lifts back the stock rating to buy from hold, which had been previously nudge down due to patent expiry worries. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 04, 2025 03:12 ET (08:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.